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EDITORIAL COMMENT
Guidelines for Surgical Standby
for Coronary Angioplasty:
Should They be Changed?*
Paolo Angelini, MD
Houston, Texas
In this issue of the Journal, Wharton et al. (1) report their
experience in performing coronary angioplasty for acute
myocardial infarction at two community hospitals, both of
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which being geographically remote from the nearest cardio-
vascular surgery facility. Their article re-addresses some
fundamental questions about the nature of, and the need
for, mandatory cardiovascular surgical standby.
CARDIOVASCULAR SURGICAL
STANDBY: WHAT DOES IT MEAN?
Aortocoronary bypass surgery has been an option for treat-
ing coronary artery occlusive disease since the late 1960s; in
that sense, it has been “standing by” for three decades as a
backup for failed cardiologic treatments. In the late 1970s,
balloon angioplasty was introduced for treating coronary
artery disease. This procedure is performed in a radiology
suite (the catheterization laboratory), on an awake patient,
in the absence of effective circulatory support. In the early
days of coronary angioplasty, catheter devices were far from
reliable, entailing a high risk of coronary dissection, plaque
disruption, elastic recoil, clot formation and other serious
complications. To improve the safety of catheter coronary
interventions, the founder of balloon angioplasty, Dr. An-
dreas Gruntzig, initiated the practice of having a cardiovas-
cular suite and appropriate personnel (including a surgical
team) ready and available next to the catheterization labo-
ratory during coronary angioplasty.
In their 1982 guidelines (2), the American Heart Asso-
ciation (AHA) and the American College of Cardiology
(ACC) endorsed Gruntzig’s original practice when they
recommended that obligatory surgical standby be available
for all coronary angioplasty procedures. Even during the
early years, however, it became clear to experienced angio-
plasty operators that active surgical standby was not strictly
necessary for most of the patients treated at large, highly
experienced cardiovascular centers (3). The literature con-
tains a few reports (reviewed by Wharton et al.), concerning
the safety, efficacy and cost-efficiency of performing elective
coronary angioplasty in hospitals that lack a cardiovascular
surgery department. This practice has never become estab-
lished, at least in the U.S., and controlled prospective
multicenter trials have never been carried out to validate its
safety. Currently—mainly because of medical, legal and
institutional concerns—the accepted standard is still to
perform coronary angioplasty only at institutions that offer
cardiovascular surgical services on the same premises. This
requirement was reiterated in 1993 by the ACC and AHA
guidelines (4). In most U.S. cardiovascular centers, however,
it has become common practice to rely on preoperative risk
assessment and to institute different degrees of surgical
standby (in some cases virtual, in other cases actual),
especially in light of cost-efficiency considerations.
Coronary Stenting Reduces the Need for Surgical
Standby. Since the introduction and popularization of
coronary stenting in the early 1990s, the already weakening
case for mandatory surgical standby during coronary angio-
plasty has become more tenuous. In the first years of
experience with fixed-wire balloon catheters, the incidence
of urgent coronary bypass surgery ranged from 10% to 25%;
by the late 1980s, the incidence had decreased to 2% to 5%,
and since 1995, it has been less than 1% (5–7). Now that
coronary stents are used in 60% to 80% of coronary
angioplasty cases in major interventional cardiology depart-
ments worldwide, mandatory surgical standby during coro-
nary angioplasty seems out of touch with reality and is
certainly not cost-effective. In fact, active surgical standby
implies the actual preparation of a surgical suite and a
primed cardiopulmonary bypass pump and circuit as well as
the ready availability of anesthesia, perfusion and surgical
teams. Even if these services are not used, the cost of
preparing and keeping them available ranges from 1,000 to
1,500 U.S. dollars. Interestingly, many U.S. health care
providers have followed the example of the federal Health
Care Financing Administration (HCFA), which adminis-
ters Medicare and Medicaid and has introduced fundamen-
tal “innovations” in health care. Since 1993, HCFA stopped
reimbursing for surgical standby during coronary angio-
plasty.
Does Angioplasty for Acute Myocardial Infarction Ne-
cessitate Surgical Standby? The use of angioplasty as a
primary means of urgent revascularization in the treatment
of acute myocardial infarction has become a common
approach for reasons that have been extensively discussed in
the recent literature (5,8,9). In this setting, the cost/benefit
ratio for surgical standby is even less favorable than in the
setting of elective angioplasty. During the early phase (more
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than 3 h and less than 15 to 30 days) after an acute
myocardial infarction, the patient is generally a poor oper-
ative candidate and is rarely referred for surgical treatment.
At well-equipped centers with experienced angioplasty op-
erators, the probability of successful guidewire passage is
about 99% in patients who undergo angioplasty during this
phase; moreover, balloon (and better yet, stent) angioplasty
is 95% to 99% successful in reducing the degree of stenosis
to less than 50%. The no-reflow phenomenon—flow less
than Thrombolysis in Myocardial Infarction (TIMI) grade
2 to 3 in the presence of a nonstenotic lesion—is a persistent
problem, especially in hearts revascularized more than 3 h
after the onset of chest pain, but surgical revascularization,
per se, would not favorably affect this phenomenon. More-
over, distal clot embolization, a relatively common although
seldom-recognized complication of acute myocardial infarc-
tion angioplasty, cannot be treated effectively even with
coronary artery bypass surgery. In contrast, balloon coun-
terpulsation or aggressive use of a left ventricular assist
device may improve the prognosis for both of these condi-
tions.
In their 1993 Guidelines for Percutaneous Transluminal
Coronary Angioplasty, the ACC and the AHA recognized
the special nature of angioplasty for acute myocardial
infarction with respect to the need for surgical standby.
According to these guidelines, well-trained operators, in
well-equipped laboratories, may perform angioplasty in
high-risk cases of acute myocardial infarction even in the
absence of active surgical standby, because angioplasty
clearly yields better results than intravenous thrombolysis in
some subsets of patients.
Since 1993, we have seen the advent of new-generation
stents that offer excellent performance in the setting of acute
myocardial infarction (5,7); we have also seen the introduc-
tion of new anticoagulant regimens, especially those based
on the usage of newer antiplatelet agents (10), that offer
well-proven efficacy during angioplasty for acute myocardial
infarction (11–13). Because of these advances, the general
opinion is that mandatory surgical standby during angio-
plasty for acute myocardial infarction is no longer necessary.
However, in this setting, any catheter intervention requires
a highly trained team and a broad range of interventional
devices, which one would hardly expect to find in hospitals
without elective angioplasty and cardiac surgery programs.
THE EXPERIENCE OF WHARTON AND COLLEAGUES
Wharton and colleagues (1) used an adapted angioplasty
protocol and policy in an atypical situation. Their approach
involved routine, systematic, emergency angiography in
patients clinically suspected of having an acute myocardial
infarction, followed by routine “angioplasty if needed and
deemed likely to succeed,” mainly using only balloon cath-
eters; the procedures were carried out at two hospitals, each
of which lacked a surgical program and was located 45 to 55
minutes (by ground ambulance) away from the nearest
cardiac surgery center. Apparently, both practices (routine
emergency angiography and routine angioplasty in a center
lacking surgical standby) were prospectively approved as
exceptions to accepted guidelines by competent institutional
review boards. Did the protocol allow the authors to reach
meaningful conclusions about the legitimacy of these treat-
ment modalities? Was the absence of surgical standby
relevant to the results of this unusual practice?
This trial should be considered to be only an observa-
tional study with positive indications. There is no doubt that
even in the absence of surgical standby, highly trained
interventional cardiologists working in well-organized and
well-equipped catheterization laboratories and relying on
the support of competent, dedicated hospital personnel, can
obtain results similar to those commonly obtained in centers
with cardiac surgery services (which are rarely used in this
context anyway). Wharton et al. suggest that multicenter
studies be undertaken to prove that emergency angiography
and angioplasty can be safely offered universally in hospitals
without surgical backup; such studies would seem irrelevant,
however, in the United States, where cardiovascular centers
with surgical services are available in great numbers and
emergency transfer by ambulance or helicopter is possible
within a reasonable period. It seems to me that the experi-
ence of Wharton and associates reflects a general oversupply
and maldistribution of well-trained specialists in the U.S., a
trend that promotes neither cost-efficiency, optimal use of
resources, nor excellence of service, but only improved
distribution.
CONCLUSIONS
The important question that remains to be addressed,
especially in the light of recent clinical experience with
coronary stents and newer anticoagulation protocols, con-
cerns the general need for surgical backup during coronary
angioplasty in any center with a well-trained staff. Hasn’t
coronary angioplasty finally gained sufficient technological
maturity and professional confidence to be self-reliant and
free-standing? No physician or medical specialty can claim
to be totally self-sufficient, but interventional cardiologists
have gained a consistent, dependable proficiency that should
enable them to declare their independence from surgery.
Once this occurs, surgical standby will be reserved only for
exceptional circumstances, although emergency cardiac sur-
gery will remain an option for treating crises that arise in the
catheterization laboratory (during either diagnostic or inter-
ventional procedures), as well as in the emergency room or
any hospital ward. Because many patients may be properly
and successfully treated with either angioplasty or coronary
bypass surgery, the ultimate choice of treatment should
depend on balanced information, open discussion, and the
results of prospective randomized, comparative studies.
Whether the guidelines for surgical standby during coronary
angioplasty are changed or not, continued collaboration
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between cardiologists and their surgical colleagues will
remain essential for optimal clinical care.
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